Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more
Lupin Limited (LUPIN) - Net Assets
Latest net assets as of September 2025: ₹197.28 Billion INR
Based on the latest financial reports, Lupin Limited (LUPIN) has net assets worth ₹197.28 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹335.00 Billion) and total liabilities (₹137.72 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹197.28 Billion |
| % of Total Assets | 58.89% |
| Annual Growth Rate | 19.21% |
| 5-Year Change | 24.8% |
| 10-Year Change | 54.48% |
| Growth Volatility | 20.34 |
Lupin Limited - Net Assets Trend (2004–2025)
This chart illustrates how Lupin Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lupin Limited (2004–2025)
The table below shows the annual net assets of Lupin Limited from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹172.94 Billion | +20.32% |
| 2024-03-31 | ₹143.73 Billion | +14.60% |
| 2023-03-31 | ₹125.43 Billion | +2.63% |
| 2022-03-31 | ₹122.22 Billion | -11.81% |
| 2021-03-31 | ₹138.58 Billion | +10.15% |
| 2020-03-31 | ₹125.81 Billion | -8.76% |
| 2019-03-31 | ₹137.89 Billion | +1.26% |
| 2018-03-31 | ₹136.17 Billion | +0.63% |
| 2017-03-31 | ₹135.32 Billion | +20.87% |
| 2016-03-31 | ₹111.95 Billion | +25.82% |
| 2015-03-31 | ₹88.98 Billion | +27.14% |
| 2014-03-31 | ₹69.99 Billion | +32.96% |
| 2013-03-31 | ₹52.64 Billion | +28.85% |
| 2012-03-31 | ₹40.85 Billion | +22.58% |
| 2011-03-31 | ₹33.33 Billion | +28.51% |
| 2010-03-31 | ₹25.93 Billion | +80.21% |
| 2009-03-31 | ₹14.39 Billion | +11.63% |
| 2008-03-31 | ₹12.89 Billion | +47.61% |
| 2007-03-31 | ₹8.73 Billion | +48.30% |
| 2006-03-31 | ₹5.89 Billion | +20.04% |
| 2005-03-31 | ₹4.91 Billion | +13.67% |
| 2004-03-31 | ₹4.32 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lupin Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14070570000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹140.71 Billion | 81.79% |
| Common Stock | ₹913.20 Million | 0.53% |
| Other Components | ₹30.42 Billion | 17.68% |
| Total Equity | ₹172.03 Billion | 100.00% |
Lupin Limited Competitors by Market Cap
The table below lists competitors of Lupin Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MGM China Holdings Ltd
PINK:MCHVY
|
$6.42 Billion |
|
Bharat Petroleum Corporation Limited
NSE:BPCL
|
$6.42 Billion |
|
EL PUERTO LIVER.N.-VTG.C1
F:PLV1
|
$6.42 Billion |
|
China Vanke Co. Ltd
PINK:CHVKF
|
$6.43 Billion |
|
MSA Safety
NYSE:MSA
|
$6.42 Billion |
|
Voya Financial Inc
NYSE:VOYA
|
$6.41 Billion |
|
Prada Spa PK
PINK:PRDSY
|
$6.40 Billion |
|
MarketAxess Holdings Inc
NASDAQ:MKTX
|
$6.40 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lupin Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 142,902,900,000 to 172,035,000,000, a change of 29,132,100,000 (20.4%).
- Net income of 32,816,200,000 contributed positively to equity growth.
- Dividend payments of 3,653,100,000 reduced retained earnings.
- Share repurchases of 398,600,000 reduced equity.
- New share issuances of 398,600,000 increased equity.
- Other comprehensive income decreased equity by 141,991,500,000.
- Other factors increased equity by 141,960,500,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹32.82 Billion | +19.08% |
| Dividends Paid | ₹3.65 Billion | -2.12% |
| Share Repurchases | ₹398.60 Million | -0.23% |
| Share Issuances | ₹398.60 Million | +0.23% |
| Other Comprehensive Income | ₹-141.99 Billion | -82.54% |
| Other Changes | ₹141.96 Billion | +82.52% |
| Total Change | ₹- | 20.39% |
Book Value vs Market Value Analysis
This analysis compares Lupin Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 214.16x to 6.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | ₹10.73 | ₹2298.20 | x |
| 2005-03-31 | ₹12.18 | ₹2298.20 | x |
| 2006-03-31 | ₹15.49 | ₹2298.20 | x |
| 2007-03-31 | ₹21.65 | ₹2298.20 | x |
| 2008-03-31 | ₹31.21 | ₹2298.20 | x |
| 2009-03-31 | ₹34.22 | ₹2298.20 | x |
| 2010-03-31 | ₹58.63 | ₹2298.20 | x |
| 2011-03-31 | ₹73.21 | ₹2298.20 | x |
| 2012-03-31 | ₹89.52 | ₹2298.20 | x |
| 2013-03-31 | ₹115.88 | ₹2298.20 | x |
| 2014-03-31 | ₹153.45 | ₹2298.20 | x |
| 2015-03-31 | ₹196.45 | ₹2298.20 | x |
| 2016-03-31 | ₹246.55 | ₹2298.20 | x |
| 2017-03-31 | ₹297.98 | ₹2298.20 | x |
| 2018-03-31 | ₹299.50 | ₹2298.20 | x |
| 2019-03-31 | ₹302.61 | ₹2298.20 | x |
| 2020-03-31 | ₹276.92 | ₹2298.20 | x |
| 2021-03-31 | ₹303.21 | ₹2298.20 | x |
| 2022-03-31 | ₹267.67 | ₹2298.20 | x |
| 2023-03-31 | ₹272.78 | ₹2298.20 | x |
| 2024-03-31 | ₹312.54 | ₹2298.20 | x |
| 2025-03-31 | ₹375.81 | ₹2298.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lupin Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.08%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.45%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.70x
- Recent ROE (19.08%) is above the historical average (19.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 32.34% | 11.46% | 0.99x | 2.86x | ₹962.34 Million |
| 2005 | 18.77% | 7.28% | 0.93x | 2.77x | ₹429.02 Million |
| 2006 | 27.75% | 10.20% | 0.84x | 3.22x | ₹1.11 Billion |
| 2007 | 35.33% | 15.32% | 0.89x | 2.59x | ₹2.21 Billion |
| 2008 | 31.90% | 15.08% | 0.80x | 2.63x | ₹2.80 Billion |
| 2009 | 35.20% | 13.28% | 0.91x | 2.90x | ₹3.59 Billion |
| 2010 | 26.54% | 14.28% | 0.94x | 1.98x | ₹4.25 Billion |
| 2011 | 26.29% | 15.11% | 0.93x | 1.87x | ₹5.34 Billion |
| 2012 | 21.62% | 12.25% | 0.89x | 1.99x | ₹4.66 Billion |
| 2013 | 25.25% | 13.63% | 1.08x | 1.71x | ₹7.94 Billion |
| 2014 | 34.67% | 18.82% | 1.25x | 1.47x | ₹17.10 Billion |
| 2015 | 27.08% | 18.82% | 0.97x | 1.48x | ₹15.16 Billion |
| 2016 | 20.25% | 16.00% | 0.62x | 2.03x | ₹11.44 Billion |
| 2017 | 18.95% | 14.73% | 0.65x | 1.97x | ₹12.08 Billion |
| 2018 | 1.85% | 1.59% | 0.60x | 1.94x | ₹-11.06 Billion |
| 2019 | 4.41% | 4.14% | 0.52x | 2.03x | ₹-7.68 Billion |
| 2020 | -2.15% | -1.75% | 0.62x | 1.99x | ₹-15.23 Billion |
| 2021 | 8.81% | 8.02% | 0.64x | 1.71x | ₹-1.64 Billion |
| 2022 | -12.57% | -9.31% | 0.75x | 1.80x | ₹-27.43 Billion |
| 2023 | 3.45% | 2.58% | 0.72x | 1.84x | ₹-8.16 Billion |
| 2024 | 13.40% | 9.57% | 0.83x | 1.68x | ₹4.85 Billion |
| 2025 | 19.08% | 14.45% | 0.78x | 1.70x | ₹15.61 Billion |
Industry Comparison
This section compares Lupin Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lupin Limited (LUPIN) | ₹197.28 Billion | 32.34% | 0.70x | $6.42 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |